| Issue Date | Title | Author(s) |
| 2019-09-04 | Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis | Sutton, SK; Cheung, BB; Massudi, H; Tan, O; Koach, J; Mayoh, C; Carter, DR; Marshall, GM |
| 2021-03-03 | A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma | Cheung, BB; Kleynhans, A; Mittra, R; Kim, PY; Holien, JK; Nagy, Z; Ciampa, OC; Seneviratne, JA; Mayoh, C; Raipuria, M; Gadde, S; Massudi, H; Wong, IPL; Tan, O; Gong, A; Suryano, A; Diakiw, SM; Liu, B; Arndt, GM; Liu, T; Kumar, N; Sangfelt, O; Zhu, S; Norris, MD; Haber, M; Carter, DR; Parker, MW; Marshall, GM |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2016-08-09 | A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. | Sutton, SK; Carter, DR; Kim, P; Tan, O; Arndt, GM; Zhang, XD; Baell, J; Noll, BD; Wang, S; Kumar, N; McArthur, GA; Cheung, BB; Marshall, GM |
| 2020-11-12 | Withaferin A activates TRIM16 for its anti-cancer activity in melanoma. | Nagy, Z; Cheung, BB; Tsang, W; Tan, O; Herath, M; Ciampa, OC; Shadma, F; Carter, DR; Marshall, GM |
| 2023-04-01 | Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma. | Seneviratne, JA; Carter, DR; Mittra, R; Gifford, A; Kim, PY; Luo, J-S; Mayoh, C; Salib, A; Rahmanto, AS; Murray, J; Cheng, NC; Nagy, Z; Wang, Q; Kleynhans, A; Tan, O; Sutton, SK; Xue, C; Chung, SA; Zhang, Y; Sun, C; Zhang, L; Haber, M; Norris, MD; Fletcher, JI; Liu, T; Dilda, PJ; Hogg, PJ; Cheung, BB; Marshall, GM |
